CN105997857A - Injection for treating porcine mastitis - Google Patents
Injection for treating porcine mastitis Download PDFInfo
- Publication number
- CN105997857A CN105997857A CN201610499665.0A CN201610499665A CN105997857A CN 105997857 A CN105997857 A CN 105997857A CN 201610499665 A CN201610499665 A CN 201610499665A CN 105997857 A CN105997857 A CN 105997857A
- Authority
- CN
- China
- Prior art keywords
- injection
- diethylstilbestrol
- mastitis
- swine udder
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 29
- 239000007924 injection Substances 0.000 title claims abstract description 29
- 208000004396 mastitis Diseases 0.000 title abstract description 14
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims abstract description 17
- 229960000452 diethylstilbestrol Drugs 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 10
- 241000282898 Sus scrofa Species 0.000 claims description 33
- 210000000481 breast Anatomy 0.000 claims description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 claims description 5
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 abstract description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 abstract description 4
- 229940049954 penicillin Drugs 0.000 abstract description 4
- 229940088710 antibiotic agent Drugs 0.000 abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 12
- 210000005075 mammary gland Anatomy 0.000 description 10
- 229940079593 drug Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010021718 Induced labour Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- -1 complement Proteins 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000001755 duct epithelial cell Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 239000002661 non steroidal estrogen Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to application of diethylstilbestrol in preparation of a medicine for treating porcine mastitis. The structural formula of diethylstilbestrol is as shown in the specification. The invention further relates to an injection for treating porcine mastitis. The injection comprises diethylstilbestrol, and preferably comprises antibiotics. The injection can be used for effectively treating porcine mastitis, the cure rate can be further improved by combining diethylstilbestrol and penicillin, the treatment period can be shortened, and the usage of penicillin can be reduced.
Description
Technical field
The present invention relates to Veterinary Medicine field, more specifically it relates to a kind of note for treating swine udder
Penetrate liquid.
Background technology
Mastitis infects, mainly due to antibacterial, a kind of inflammation that mammary gland tissue causes.Papillary duct is that antibacterial is invaded
Enter mammary gland and cause a main path of infection, papillary duct epithelial cells keratin etc. under health status
There is the material of antibacterial action, be that antibacterial invades the first line of defence that runs into of mammary gland.When papillary duct is owing to squeezing
The reasons such as milk are damaged, and the function of epithelial cells antibiotic substance wrecks, and antibacterial is easily accessible
Mammary gland.When antibacterial breaks through the physical barriers of nipple, and the second defence line run into after invading mammary gland is in mammary gland
Body fluid and cellularity defending factors.Humoral factor includes immunoglobulin, complement, lactoferrin, molten
Bacterium enzyme and peroxide enzyme system etc.；Cellularity defending factors include macrophage, polymorphonuclear leukocyte and
Lymphocyte etc..If after antibacterial entrance mammary gland, the virulence of antibacterial is strong, quantity is many or mammary gland defense mechanism is thin
Weak, then antibacterial can break through second defence line, settles down, breeds, cause disease in mammary gland；If antibacterial
Virulence is low, quantity is few or mammary gland defense function is powerful, then antibacterial is eliminated, and will not produce mastopathy.
Sow mastitis is a kind of disease that nursing sow is relatively conventional.The intestinal mastitis of sow is sent out
Sick rate is higher, and according to showing stopping breast phase sow necropsy statistics, macroscopic mastitis occurs in sow
Pathological changes is up to 82%.This disease generation can reduce the milk yield of pig, can cause blind teat time serious, and impact is to son
The nurture of pig.Its mortality rate of piglet of morbidity sow suckling is 55.8%, and the piglet of normal sow suckling
Mortality rate is only 17.2%.Therefore, fast and effeciently treatment suffer from the sow in lactation of mastitis can be by
The economic loss thus brought is down to minimum.
At present, the method for the treatment of swine udder be the liquid drugs injection dosage form using antibiotic, antibacterials to make or
The product of injectable powder type is treated, and is required to pig drug administration by injection.But, it is used alone effects of antibiotics
Be not the best, general cure rate at 70-80%, and, if using antibiotic in a large number for a long time, hold
Pathogenic bacteria is easily made to produce drug resistance.
Accordingly, it would be desirable to a kind of new medicament treating swine udder.
Summary of the invention
Diethylstilbestrol, also referred to as diethylstilbestrol, be the non steroidal estrogen material of a kind of synthetic, and it is changed
Formula is C18H20O2, structural formula is as follows:
It is functional that this compound is mainly used in that estrogen is low or deficiency disease and hormonal balance disorder cause
Hemorrhage, amenorrhea, it may also be used for before stillborn fetus induced labor, to improve the myometrium sensitivity to oxytocin, with
And carcinoma of prostate thus breath therapy.
Inventor in the research process to swine udder, it was unexpectedly found that, suffering from mastitis
The affected part injection diethylstilbestrol of sow can cure mastitis.
Find based on this, the invention provides diethylstilbestrol answering in preparing swine udder medicine
With.
Present invention also offers a kind of injection for treating swine udder, it comprises diethylstilbestrol.
Preferably, the content of described diethylstilbestrol is 1-2mg/ml.
When affected pig symptom ratio is time more serious, and the described injection for treating swine udder further preferably comprises anti-
Raw element, such as penicillin sodium.
Preferably, the concentration of described penicillin sodium is 15-20 ten thousand units/ml.
Preferably, the solvent of the described injection for treating swine udder is aseptic water or physiology salt
Water.
Present invention also offers and a kind of described preparing swine udder for treating the injection of swine udder
Application in medicine
Detailed description of the invention
Being described principle and the feature of the present invention below in conjunction with example, example is served only for explaining this
Invention, is not intended to limit the scope of the present invention.
1 for treating the preparation of the injection of swine udder
By table 1 showing, composition is formulated for treating the injection of swine udder
Table 1 is for treating the composition of the injection of swine udder
| Embodiment | Diethylstilbestrol (mg/ml) | Penicillin sodium (ten thousand units/ml) | Solvent |
| Embodiment 1 | 1 | 0 | Normal saline |
| Embodiment 2 | 1.5 | 0 | Normal saline |
| Embodiment 3 | 2 | 0 | Normal saline |
| Embodiment 4 | 2 | 15 | Normal saline |
| Comparative example | 0 | 50 | Normal saline |
2. use the injection for treating swine udder in above example
Injection in above-described embodiment is applied to the affected part suffering from the pig of mastitis, twice daily, directly
To mastitis transference cure, when medication is not still cured after 10 days, discontinue medication, it is determined that
For not curing.
Application process is: drawing 6ml injection with asepsis injector, the breast in affected pig suffers from leaf base
Inwardly stabbing 2-3cm diagonally, then injected by injection, every kind of injection for treating 20 only changes the trouble of mastitis
Pig, therapeutic outcome is as shown in table 2.Therapeutic outcome shows, but, diethylstilbestrol can effectively treat pig breast
Fang Yan, and by diethylstilbestrol and penicillin with the use of being further noted that cure rate, when shortening treatment
Between, and reduce penicillin consumption.
The therapeutic effect of each injection of table 2
| Embodiment | Cure number | Cure rate | Average cure time (my god) |
| Embodiment 1 | 15 | 75% | 4 |
| Embodiment 2 | 16 | 80% | 4 |
| Embodiment 3 | 18 | 90% | 3 |
| Embodiment 4 | 19 | 95% | 3 |
| Comparative example | 17 | 85% | 5 |
The foregoing is only presently preferred embodiments of the present invention, not in order to limit the present invention, all in the present invention
Spirit and principle within, any modification, equivalent substitution and improvement etc. made, should be included in this
Within bright protection domain.
Claims (8)
1. diethylstilbestrol application in preparing swine udder medicine, it is characterised in that described ethylene
The structural formula of female phenol is as follows:
2. the injection being used for treating swine udder, it is characterised in that comprise diethylstilbestrol, described
The structural formula of diethylstilbestrol is as follows:
Injection for treating swine udder the most according to claim 2, it is characterised in that
The content of described diethylstilbestrol is 1-2mg/ml.
Injection for treating swine udder the most according to claim 2, it is characterised in that
Also comprise antibiotic.
Injection for treating swine udder the most according to claim 4, it is characterised in that
Described antibiotic is penicillin sodium.
Injection for treating swine udder the most according to claim 5, it is characterised in that
The concentration of described penicillin sodium is 15-20 ten thousand units/m l.
7. according to the injection for treating swine udder according to any one of claim 2-6, its
Being characterised by, the solvent of the described injection for treating swine udder is aseptic water or normal saline.
8. existing for the injection treating swine udder as according to any one of claim 2-7
Prepare the application in swine udder medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610499665.0A CN105997857A (en) | 2016-06-29 | 2016-06-29 | Injection for treating porcine mastitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610499665.0A CN105997857A (en) | 2016-06-29 | 2016-06-29 | Injection for treating porcine mastitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105997857A true CN105997857A (en) | 2016-10-12 |
Family
ID=57105373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610499665.0A Pending CN105997857A (en) | 2016-06-29 | 2016-06-29 | Injection for treating porcine mastitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105997857A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013049773A1 (en) * | 2011-09-30 | 2013-04-04 | Vanderbilt University | Antiviral therapies with phospholipase d inhibitors |
| CN103118670A (en) * | 2010-06-01 | 2013-05-22 | 欧鲁普雷图联邦大学 | Nanoparticulate composition containing antibiotics for intramammary administration in animals |
| CN103561720A (en) * | 2011-03-03 | 2014-02-05 | 尼克美制药有限公司 | Diethylstilbestrol dosage forms and their use in the treatment of prostate or breast cancer |
-
2016
- 2016-06-29 CN CN201610499665.0A patent/CN105997857A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103118670A (en) * | 2010-06-01 | 2013-05-22 | 欧鲁普雷图联邦大学 | Nanoparticulate composition containing antibiotics for intramammary administration in animals |
| CN103561720A (en) * | 2011-03-03 | 2014-02-05 | 尼克美制药有限公司 | Diethylstilbestrol dosage forms and their use in the treatment of prostate or breast cancer |
| WO2013049773A1 (en) * | 2011-09-30 | 2013-04-04 | Vanderbilt University | Antiviral therapies with phospholipase d inhibitors |
Non-Patent Citations (6)
| Title |
|---|
| N.A.FRANK ET AL: "The effect of Diethylstilbestrol and Progesterone on the Growth of four Mastitis-Producing Bacteria", 《AM.J.VET.RES.》 * |
| SAAD,A.M. AND KAARTINEN,L.: "Influence of estradiol administration to lactating cows on bacterial growth in milk whey", 《JOURNAL OF VETERINARY MEDICINE》 * |
| 周玖瑶 曾南主编: "《药理学实验》", 31 January 2015, 中国医药科技出版社 * |
| 孙吉 等: "三合激素治疗奶牛乳房炎、子宫炎的疗效观察", 《中国兽医杂志》 * |
| 王哲 等主编: "《兽医手册 第四版》", 31 January 2001, 北京：科学出版社 * |
| 邓国华 等主编: "《新编养猪实用技术》", 30 June 2006, 中国农业出版社 农村读物出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102247318B (en) | Oxytetracycline uterus injectant and preparation method thereof | |
| CN103977017A (en) | Anti-parasitic injection for veterinary use and preparation method thereof | |
| CN104938822A (en) | Feed additive for reducing cow body cells and treating recessive mastitis and preparation method of feed additive | |
| JP2018127399A (en) | Therapeutic agent and method for very acute or acute breast inflammation of cattle in lactation period | |
| CN101439044B (en) | Compound povidone-iodine gel for treating cow mastitis, preparation method and application in pharmacy | |
| CN103893108A (en) | Breast injectant prescription of cefquinome sulfate in dry milk period and preparation method thereof | |
| CN102579582A (en) | Application of magnolia total phenol in medicament for treating cow mastitis | |
| CN105997857A (en) | Injection for treating porcine mastitis | |
| RU2367433C1 (en) | Preparation for mastitis treatment in lactating cows | |
| CN104382923A (en) | Lincomycin hydrochloride breast injectant for dairy cow and preparation method thereof | |
| CN104642256A (en) | Fifty-fifty pig-raising method | |
| CN104382898A (en) | Compound breast injectant with amoxicillin and preparation method thereof | |
| CN111494509A (en) | A Chinese medicinal injection for treating mastitis of milk cow, and its preparation method | |
| CN103386115A (en) | Application of thymopentin in preparing medicine used for treating mastitis | |
| CN104127429A (en) | Drinking water agent for preventing and treating livestock and poultry respiratory tract diseases and preparation method thereof | |
| CN108524494A (en) | Application and potassium dehydroandrographolide succinate animal medicament of the potassium dehydroandrographolide succinate in preparing veterinary drug | |
| CN104188987A (en) | Formula and preparation method of veterinary injectant for preventing and treating endometritis | |
| RU2320325C1 (en) | Method for treating inspecific mastitis in cows | |
| CN105267301A (en) | Traditional Chinese medicine composition for reducing somatic cell count of dairy cows and its preparation method | |
| CN110151779A (en) | A kind of composition for the treatment of frog head tilting disease and its application | |
| Langer et al. | Sulfamethazine blood and milk concentrations in dairy cows | |
| CN102805866A (en) | Pharmaceutic preparation for livestock and application thereof | |
| CN101966245B (en) | Compound injection for curing viral diseases in livestock and poultry and preparation method thereof | |
| RU2239445C1 (en) | Method for treating subclinical mastitis in lactating cows | |
| RU2537244C1 (en) | Medication for treating clinical mastitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161012 |